The need for new drugs against tuberculosis - Obstacles, opportunities, and next steps
The need for new drugs against tuberculosis - Obstacles, opportunities, and next steps
复制标题
DOI：
10.1164/ajrccm.163.5.2007122
复制
发表时间：
2001-04-01
影响因子：
24.7
通讯作者：
Nunn, PP
中科院分区：
文献类型：
--
作者：
O'Brien, RJ;Nunn, PP
自从引入用于治疗结核病的新型化合物以来已经将近30年了，尽管在过去的二十年中许多人呼吁开发新的抗结核药物，但除了少数例外，制药行业对在这一领域开展工作几乎没有兴趣。这种缺乏兴趣在很大程度上是由于两个关键的看法：现有药物足以控制结核病，而且无法实现足够的利润来证明将新的结核病药物推向市场的费用是合理的。这篇文章将认为，新的药物是迫切需要的，新的机会，真实的进步存在。私营部门与公共部门的伙伴关系是一种正在尝试的新办法，可能会克服现有的财政障碍，并导致在未来十年开发出主要的新药。
It has been nearly 30 years since the introduction of a novel compound for the treatment of tuberculosis, Despite many calls for the development of new antituberculosis drugs during the past two decades, the pharmaceutical industry has, with few exceptions, indicated little interest in undertaking work in this area. This lack of interest is due in large part to two key perceptions: that currently available drugs are adequate for the control of tuberculosis and that sufficient profit could not be realized to justify the expense of bringing a new tuberculosis drug to market. This article will argue that new drugs are badly needed and that new opportunities for real progress exist. Private-public sector partnerships, a new approach that is being tried, may overcome existing financial impediments and lead to the development of major new drugs in the coming decade.